137 related articles for article (PubMed ID: 3400639)
1. Therapeutic effects of oral sorbent in undialyzed uremia.
Sanaka T; Sugino N; Teraoka S; Ota K
Am J Kidney Dis; 1988 Aug; 12(2):97-103. PubMed ID: 3400639
[TBL] [Abstract][Full Text] [Related]
2. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure.
Nakamura T; Kawagoe Y; Matsuda T; Ueda Y; Shimada N; Ebihara I; Koide H
Kidney Blood Press Res; 2004; 27(2):121-6. PubMed ID: 15051932
[TBL] [Abstract][Full Text] [Related]
3. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients.
Niwa T; Tsukushi S; Ise M; Miyazaki T; Tsubakihara Y; Owada A; Shiigai T
Miner Electrolyte Metab; 1997; 23(3-6):179-84. PubMed ID: 9387112
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: two-year study.
Takahashi N; Kawaguchi T; Suzuki T
Int J Urol; 2005 Jan; 12(1):7-11. PubMed ID: 15661048
[TBL] [Abstract][Full Text] [Related]
5. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
[TBL] [Abstract][Full Text] [Related]
6. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of indoxyl-beta-D-glucuronide in uremic serum: suppression of its production by oral sorbent and efficient removal by hemodialysis.
Niwa T; Miyazaki T; Tsukushi S; Maeda K; Tsubakihara Y; Owada A; Shiigai T
Nephron; 1996; 74(1):72-8. PubMed ID: 8883023
[TBL] [Abstract][Full Text] [Related]
8. Review of the efficacy of AST-120 (KREMEZIN
Asai M; Kumakura S; Kikuchi M
Ren Fail; 2019 Nov; 41(1):47-56. PubMed ID: 30732506
[TBL] [Abstract][Full Text] [Related]
9. Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats.
Niwa T; Ise M; Miyazaki T; Meada K
Nephron; 1993; 65(1):82-7. PubMed ID: 8413797
[TBL] [Abstract][Full Text] [Related]
10. Effects of oral adsorbent in the rat model of chronic renal failure.
Yoshida Y; Sakai T; Ise M
Nephron; 1992; 62(3):305-14. PubMed ID: 1436344
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of oral absorbent AST-120 in lipid abnormalities in experimental uremic rats.
Yamakado M; Ise M
Kidney Int Suppl; 1999 Jul; 71():S190-2. PubMed ID: 10412773
[TBL] [Abstract][Full Text] [Related]
12. Clinical analysis of renoprotective responding patients administrated with oral adsorbent in chronic renal failure secondary to chronic glomerulonephritis.
Sanaka T; Akizawa T; Koide K; Koshikawa S
Ther Apher Dial; 2003 Apr; 7(2):269-78. PubMed ID: 12918955
[TBL] [Abstract][Full Text] [Related]
13. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease.
Yorioka N; Kiribayashi K; Naito T; Ogata S; Yokoyama Y; Kyuden Y; Ogawa T; Wada K; Hayashi K; Hirabayashi A
J Nephrol; 2008; 21(2):213-20. PubMed ID: 18446716
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy.
Sanaka T; Akizawa T; Koide K; Koshikawa S
Ther Apher Dial; 2004 Jun; 8(3):232-40. PubMed ID: 15154877
[TBL] [Abstract][Full Text] [Related]
15. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases.
Ueda H; Shibahara N; Takagi S; Inoue T; Katsuoka Y
Ther Apher Dial; 2007 Jun; 11(3):189-95. PubMed ID: 17498000
[TBL] [Abstract][Full Text] [Related]
16. [Effect of oral sorbent, AST-120, on serum concentration of indoxyl sulfate in uremic rats].
Niwa T; Yazawa T; Maeda K; Ise M; Sugano M; Kodama T; Uehara Y
Nihon Jinzo Gakkai Shi; 1990 Jun; 32(6):695-701. PubMed ID: 2120492
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure.
Maeda K; Hamada C; Hayashi T; Shou I; Wakabayashi M; Fukui M; Horikoshi S; Tomino Y
J Int Med Res; 2009; 37(1):205-13. PubMed ID: 19215692
[TBL] [Abstract][Full Text] [Related]
18. Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single-Arm, Open-Label, Multi-Center Study.
Hwang YC; Kim SW; Hur KY; Cha BS; Kim IJ; Park TS; Baik SH; Yoon KH; Lee KW; Lee IK; Lee MK
J Korean Med Sci; 2019 Apr; 34(15):e117. PubMed ID: 31001934
[TBL] [Abstract][Full Text] [Related]
19. Excess morbidity in patients starting uremia therapy without prior care by a nephrologist.
Ifudu O; Dawood M; Homel P; Friedman EA
Am J Kidney Dis; 1996 Dec; 28(6):841-5. PubMed ID: 8957035
[TBL] [Abstract][Full Text] [Related]
20. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients.
Lee CT; Hsu CY; Tain YL; Ng HY; Cheng BC; Yang CC; Wu CH; Chiou TT; Lee YT; Liao SC
Blood Purif; 2014; 37(1):76-83. PubMed ID: 24576840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
